
    
      This is an open-label, pilot study to evaluate the safety of Adriamycin and cyclophosphamide
      (AC) administered every 2 weeks for 4 cycles followed by Abraxane administered every 2 weeks
      for 4 cycles as adjuvant therapy for patients with limited stage breast cancer.
    
  